Waldenström’s macroglobulinemia is a low-grade lymphoplasmacytic lymphoma characterized by a circulating monoclonal IgM. The clinical manifestations are due to deposition of IgM in liver, spleen, and/or lymph nodes. Related symptoms include anemia and complications of the hyperviscosity syndrome. Renal involvement in classical cases of Waldenström’s macroglobulinemia is rare, and the pathological hallmark finding in the renal biopsy specimen is a thrombotic microangiopathy. We report the case of a 73-year-old female with the diagnosis of pernicious anemia for 2 years before she presented with acute renal failure. A renal biopsy performed suggested the diagnosis of myeloma cast nephropathy. However, bone marrow biopsy specimens and hematological studies did not support this diagnosis. Serum and urinary protein electrophoresis revealed a monoclonal lambda subtype IgM. Ultrasound imaging showed an enlarged spleen. The diagnosis of cast nephropathy in a patient with Waldenström’s macroglobulinemia was made. She underwent treatment with fludarabine and plasmapheresis/hemodyalisis with dramatic improvement of her renal function.

Keywords:
Cast nephropathy, Waldenström’s macroglobulinemia, Renal biopsy
1.
Gertz MA, Fonseca R, Rajkumar SV: Waldenström’s macroglobulinemia. Oncologist 2000;5:63–67.
2.
Andriko JA, Aguilera NS, Chu WS, Nandedkar MA, Cotelingam JD: Waldenström’s macroglobulinemia: A clinicopathologic study of 22 cases. Cancer 1997;80:1926–1935.
3.
Morel-Maroger L, Stricker LJ, Preud’homme JL, D’Amico G, Stricker GE: Monoclonal gammopathies, mixed cryoglobulinemias, and lymphomas; in Tisher CC, Brenner BM (eds): Renal Pathology with Clinical and Functional Correlations, ed 2. Philadelphia, Lippincott, 1994, vol II, pp 1442–1490.
4.
Churg J, Bernstein J, Glassock RJ: in Renal Diseases: Classification and Atlas of Glomerular Diseases, ed 2. Tokyo, Igaku-Shoin, 1995, pp 334–335, 368–370, 380.
5.
Veltman GA, van Veen S, Kluin-Nelemans JC, Bruijn JA, van Es LA: Renal disease in Waldenström’s macroglobulinaemia. Nephrol Dial Transplant 1997;12:1256–1259.
6.
Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr: Waldenström’s macroglobulinemia: Incidence patterns in the United States, 1988–1994. Cancer 1998;82:1078–1081.
7.
Alexanian R, Weber D, Liu F: Differential diagnosis of monoclonal gammopathies. Arch Pathol Lab Med 1999;123:108–113.
8.
Kondo H, Yokoyama K: IgM myeloma: Different features from multiple myeloma and macroglobulinaemia. Eur J Haematol 1999;63:366–368.
9.
Haghighi B, Yanagihara R, Cornbleet PJ: IgM myeloma: Case report with immunophenotypic profile. Am J Hematol 1998;59:302–308.
10.
Maniatis A: Pathophysiology of paraprotein production. Ren Fail 1998;20:821–828.
11.
Isaac J, Herrera GA: Renal biopsy as a primary diagnostic tool in plasma cell dyscrasias. Pathol Case Rev 1998;3:183–189.
12.
Diebold J, Molina T, Tissier F, le Tourneau A, Audouin J: Waldenström’s macroglobulinemia is a biological syndrome which may occur during the evolution of different types of low grade B cell lymphoma. Leukemia 1999;13:1637–1638.
13.
Allez M, Mariette X, Linares G, Bertheau P, Jian R, Brouet JC: Low-grade MALT lymphoma mimicking Waldenström’s macroglobulinemia. Leukemia 1999;13:484–485.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.